These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37067727)

  • 1. Effectiveness and Safety of Recombinant Human Follicle-Stimulating Hormone (Follitrope™) in Inducing Controlled Ovarian Stimulation in Infertile Women in Real-World Practice: a Prospective Cohort Study.
    Choo CW; Ahn YS; Kim KH; Lee JH; Moon KY; Choi BC; Kang YJ; Kim HY; Sim CH; Han JE; Kim CH; Jang EJ; Lee Y; Moon JW; Park DS; Won HJ; Kim AN; Kim JY; Kim KR; Ahn JH; Lee JY; Gwak H; Kim JH
    Reprod Sci; 2023 Sep; 30(9):2842-2852. PubMed ID: 37067727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.
    Sydow P; Gmeinwieser N; Pribbernow K; Keck C; Wiegratz I
    Reprod Biol Endocrinol; 2020 May; 18(1):54. PubMed ID: 32456636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
    Fernández Sánchez M; Višnová H; Larsson P; Yding Andersen C; Filicori M; Blockeel C; Pinborg A; Khalaf Y; Mannaerts B;
    Hum Reprod; 2022 May; 37(6):1161-1174. PubMed ID: 35451013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
    Kim CH; Ahn JW; You RM; Kim SH; Chae HD; Kang BM
    J Reprod Med; 2014; 59(1-2):63-8. PubMed ID: 24597289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.
    Oehninger S; Nelson SM; Verweij P; Stegmann BJ
    Reprod Biol Endocrinol; 2015 Oct; 13():117. PubMed ID: 26520396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed versus flexible antagonist protocol in women with predicted high ovarian response except PCOS: a randomized controlled trial.
    Luo X; Pei L; Li F; Li C; Huang G; Ye H
    BMC Pregnancy Childbirth; 2021 May; 21(1):348. PubMed ID: 33934703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of gonadotropin releasing hormone agonist long protocol and gonadotropin releasing hormone antagonist protocol in infertile women].
    Ren Y; Yang S; Yang R; Li R; Chen XN; Wang HY; Ma CH; Liu P; Qiao J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 45(6):877-81. PubMed ID: 24343066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
    Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
    Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two different starting dose of rhFSH in GnRH antagonist protocol for patients with normal ovarian reserve.
    Jia ZC; Li YQ; Li R; Hou S; Xia QC; Yang K; Wang PX; Li SM; Sun ZG; Guo Y
    Front Endocrinol (Lausanne); 2023; 14():1068141. PubMed ID: 36742378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed Gonadotropin-Releasing Hormone Antagonist Protocol
    Dong M; Sun L; Huang L; Wang F; Zhang X; Liu F
    Front Endocrinol (Lausanne); 2021; 12():690575. PubMed ID: 34867773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of antral follicle size prior to stimulation in predicting ovarian response in a multiple dose GnRH antagonist protocol.
    Lai Q; Chen C; Zhang Z; Zhang S; Yu Q; Yang P; Hu J; Wang CY
    Int J Clin Exp Pathol; 2013; 6(2):258-66. PubMed ID: 23330011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of prognostic modelling of high and low ovarian response to ovarian stimulation for IVF.
    Scheinhardt MO; Lerman T; König IR; Griesinger G
    Hum Reprod; 2018 Aug; 33(8):1499-1505. PubMed ID: 30007353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Factors related to clinical pregnancy outcomes of in vitro fertilization-embryo transfer in women with secondary infertility].
    Liu YF; Ye XQ; Zhu LL; Huang Y; Wu YQ; Xu P; Kong YJ; Liu F; Sun SJ; Zhang D
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2015 May; 44(3):237-46. PubMed ID: 26350002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.